Sex, Gender, and the Brain: The Women’s Brain Foundation and Medscape Education Announce Groundbreaking Learning Centre
The Women’s Brain Foundation (WBF), the global pioneer that has advanced the inclusion of sex- and gender-based evidence-generation in all research, drug development, and healthcare since 2017; and Medscape Education, a leading provider of medical education, are proud to announce the launch of their new learning centre focused on addressing sex and gender differences in brain and mental health care. This flagship initiative is a natural extension of prior WBF forums in which the importance of determining sex and gender differences has been discussed with the entire healthcare ecosystem – policymakers, academia, patient association, drug developers, regulators and funding agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016398625/en/
This new learning centre is associated with the “Medscape Essentials” initiative, which highlights Medscape’s commitment to addressing areas of high unmet need within medical education through self-funding of activities. Last year, Medscape self-funded one-third of its continuing/independent medical education.
This latest edition of the WBF Forum is designed to enhance awareness and understanding among healthcare professionals regarding sex and gender differences in brain health through an informative conversation among experts. This initiative aims to highlight the plethora of differences between women and men with neurologic and psychiatric disorders, an area that has long been overlooked from medical research to clinical practice.
“This initiative is vital,” said Antonella Santucionne Chadha, MD, PhD, founder and pro bono CEO of the WBF. “Healthcare professionals must understand that there exists intrinsic bias, not only in prevalence and incidence of specific diseases, but because many diseases progress differently in women than in men – and women respond differently to treatment in terms of efficacy and safety profiles. Collaborating with a platform like Medscape is important to our work because it can help us accelerate practice changes. We want to bring this evidence straight into the clinic. And the Medscape platform can help us do that.”
The global prevalence of neurologic disorders is extensive, affecting approximately 1 in 3 people worldwide. According to the most recent Global Burden of Disease Study, neurologic disorders are the leading cause of disability and the second leading cause of death globally.1 Sex and gender are independent crucial factors in health and disease outcomes. While sex differences influence disease prevalence, presentations, treatment efficacy, and side effects, gender differences – encompassing socially constructed roles, behaviours, and expressions of individual identities – also significantly impact health behaviours and disease outcomes. Unfortunately, sex and gender differences have been poorly explored in brain health.2,3
“This Medscape Essentials program will help to unveil sex and gender disparities, which historically within neuroscience research have exhibited a strong sex bias favouring males, and often omitted sex as a variable altogether,”2 shared S. Christy Rohani-Montez, PhD, Director of Clinical Strategy, Medscape Education. “Medscape's commitment to bridging the educational gaps in key areas like this supports our values surrounding health equity and our mission to be the most trusted and valued source of health information and education throughout the career of a healthcare professional.”
With a membership exceeding 13-million healthcare professionals worldwide, Medscape Education is uniquely positioned to lead the industry in recognizing and addressing sex and gender differences in health care. This initiative, focused on disparities across neurologic and psychiatric conditions, represents a significant step towards more inclusive and effective patient care, and is just one of many planned that will help address and close the gender gaps.
For more information, visit www.womensbrainproject.com and www.medscape.org.
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free accredited CME and CE courses for physicians, nurses, and other healthcare professionals.
About WebMD Health Corp.
WebMD, an Internet Brands company, is at the heart of the digital health revolution that is transforming the healthcare experience for consumers, patients, health care professionals, employers, health plans, and health systems. Through public and private online portals, mobile platforms, and health-focused publications, WebMD delivers leading-edge content and digital services that enable and improve decision-making, support and motivate health actions, streamline and simplify the health care journey, and improve patient care.
The WebMD Health Network includes WebMD Health, Medscape, WebMD Ignite (encompassing Krames, The Wellness Network and Mercury Healthcare), Jobson Healthcare Information, MediQuality, Frontline, Vitals Consumer Services, Aptus Health, PulsePoint, The Wellness Network, SanovaWorks, MNG Health, MedicineNet, eMedicineHealth, RxList, OnHealth, Medscape Education, and other owned WebMD sites. WebMD®, Medscape®, CME Circle®, Medpulse®, eMedicine®, MedicineNet®, theheart.org® and RxList® are among the trademarks of WebMD Health Corp. or its subsidiaries.
About WBF
The Women’s Brain Foundation (WBF) is an international non-profit organization based in Switzerland. We are experts from various disciplines who are applying sex- and gender-based scientific evidence to develop precision medicine, from basic science to novel technologies. We conduct, coordinate, support, and advance research related to sex and gender differences to achieve this goal. We also act as an incubator and an accelerator of women’s health innovation. We focus our research and advocacy particularly, but not exclusively, on diseases of the brain.
References:
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021). Seattle: Institute for Health Metrics and Evaluation (IHME); 2024.
- Mamlouk GM, et al. Sex bias in neuroscience research. Front Neuroendocrinol. 2020:57:100835.
- Moores G, et al. Sex differences in neurology: a scoping review. BMJ Open. 2023;13:e071200.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016398625/en/
Contacts
Jaberta Bennett
jbennett@webmd.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom